Ario Pharma Limited
http://www.ariopharma.com/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ario Pharma Limited
U.K Drug-Repurposing Program Expands, Attracts Industry Support
Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
Life Science Start-Ups: Venture Funding, February 2014
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced December 2013 through January 2014.
U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2011
Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Provesica Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice